IL21 and melanoma: We have previously reported that the tumor vaccine of the glycosylphosphatidylinositol (GPI)-anchored interleukin 21(B16F10/GPI-IL-21) in combination with the overexpression of microRNA-200c (miR200c) or with a knockdown of the zinc-finger E-box binding homeobox 1(ZEB1), which is a transcription factor [7], significantly induced immune responses to the B16F10 cells, diminished tumor growth and inhibited the melanoma epithelial to mesenchymal transition (EMT) program.